Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

BACKGROUND: Pancreatic cancer is considered as a chemoresistant neoplasm with extremely dismal prognosis. Gemcitabine is recommended as the standard agent for locally advanced or metastatic pancreatic cancer. A series of trials have been conducted to improve the outcome of advanced pancreatic cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuan, Hu, Guo-fang, Zhang, Qian-qian, Tang, Ning, Guo, Jun, Liu, Li-yan, Han, Xiao, Wang, Xia, Wang, Zhe-hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912328/
https://www.ncbi.nlm.nih.gov/pubmed/27358556
http://dx.doi.org/10.2147/DDDT.S105442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912328/
https://www.ncbi.nlm.nih.gov/pubmed/27358556
http://dx.doi.org/10.2147/DDDT.S105442

Ejemplares similares